5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implement...
5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported
About this item
Full title
Author / Creator
Publisher
London: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
London: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
Background and ImportanceThe COVID-19 pandemic has highlighted the important role that hospital pharmacists play in improving pharmacotherapy outcomes. Paxlovid® (Nirmatrelvir/ritonavir) was recently granted an Emergency Use Authorisation for the treatment of mild to moderate COVID-19. However, the use of Paxlovid® with certain other drugs in high-...
Alternative Titles
Full title
5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2789973558
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2789973558
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2023-eahp.316
